AR and breast cancer: Interestingly, the LAR-subtype is closely related to the L2 (ER + luminal BC) hormone-responsive cells, and its cell lines were uniquely sensitive to the AR antagonist Bicalutamide; therefore, the next-generation AR antagonist Enzalutamide is currently being evaluated in AR-positive (AR+) TNBC in combination with Paclitaxel (20).